Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

What Kardigan's IPO Means for Heart Health Innovations

Kardigan, a cardiovascular biotech firm, is gearing up for a significant IPO, aiming to raise approximately $320 million through its planned Nasdaq listing. The company plans to offer 23.3 million shares priced between $14 and $16 each. If the final price falls in the middle of this range, Kardigan could see net proceeds of over $320 million, with potential to increase to $369 million if underwriters opt for additional shares. Led by CEO Tassos Gianakakos, who previously helmed MyoKardia, Kardigan is focused on developing innovative therapies for heart conditions.

This IPO is particularly relevant for people interested in heart health and longevity. Kardigan’s lead drug, danicamtiv, is in advanced trials for genetic dilated cardiomyopathy, a condition that can severely impact heart function. The company is also investing in ataciguat, which aims to slow the progression of calcific aortic valve stenosis, and tonlamarsen, designed to help regulate blood pressure for those recently hospitalized for hypertension. These developments could lead to new treatment options that improve cardiovascular health, potentially benefiting many individuals at risk for heart disease.

The research is at various stages, with danicamtiv in a phase 2b/3 program and ataciguat currently in phase 2b trials. While these drugs show promise, they are still undergoing testing, and their effectiveness in humans is not yet fully established. Kardigan’s ambitious plans reflect a growing trend in the biotech sector, with increasing investor interest in innovative therapies that could transform cardiovascular care.

As Kardigan moves forward, it’s a reminder of the importance of supporting companies that focus on groundbreaking treatments for heart health. Staying informed about these advancements can empower you to make better health decisions and advocate for innovative therapies in cardiovascular care.